Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma

Shaukat Ali*1,2, Syed M Uddin1, Ayesha Ali1, Fatima Anjum2, Rashid Ali1, Elisha Shalim1, Mujtaba Khan1, Iqra Ahmed1, Sheikh M Muhaymin1, Uzma Bukhari3, Shobha Luxmi4, Abdul S Khan5 & Saeed Quraishy6

1Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan
2Dow Research Institute of Biotechnology & Biomedical Sciences, Dow University of Health Sciences, Karachi, Pakistan
3Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
4Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan
5National Control Laboratory for Biologicals, Islamabad, Pakistan
6Dow University of Health Sciences, Karachi, Pakistan
*Author for correspondence: ali.shaukat@duhs.edu.pk

Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 ± 30 cut-off index) that of the PCP (36 ± 8.5 cut-off index) and mean protein concentration was found to be 46 ± 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT 04521309).
the registration of multiple clinical trials globally, and the first evidence that anti-SARS-CoV-2 antibodies present in plasma could effectively treat COVID-19 patients came from the work of Cheng et al. [10]. However, reports regarding the safety and efficacy of convalescent plasma in COVID-19 infection are still inconclusive due to limited sample size, study design, early termination of the trial and/or unavailability of results [11]. High doses of nonspecific intravenously administrable immunoglobulin (IVIG) are reported to improve recovery in severe cases (when given at an early stage of the disease) by suppressing inflammatory markers through immune modulation [12,13]. Polyclonal and monoclonal immunoglobulin preparations have been used for prophylaxis and treatment of viral infections such as respiratory syncytial virus infection and human CMV infection [14]. Polyclonal anti-COVID-19 IVIG (C-IVIG) is therefore expected to be an effective approach for treating COVID-19 patients by neutralizing SARS-CoV-2, limiting its dissemination inside the patient and thus limiting the course of disease [15].

Caprylic acid-based plasma fractionation is a relatively simple and practical method that can be used even in technologically less advanced countries in this time of pandemic for widespread availability of hyperimmune C-IVIG. Caprylic acid-based protein purification has been successfully applied for commercial production of equine plasma-derived antivenoms [16]. El-Ekiaby et al. reported fractionation of human plasma minipools using caprylic acid precipitation to produce IgG preparations [17]. Due to fewer processing steps, robust viral inactivation, expected high purity and product yield, caprylic acid precipitation is expected to be an ideal method for production of safe and effective C-IVIG.

This study aims to demonstrate the feasibility of the modified caprylic acid method for C-IVIG production from pooled convalescent plasma (PCP) of COVID-19 recovered individuals.

Materials & methods

Donor selection & plasma collection
Convalescent plasma was collected from consenting COVID-19 recovered individuals meeting the inclusion criteria: prior diagnosis of COVID-19 documented by a laboratory test, complete resolution of symptoms at least 14 days prior to donation, female donors negative for HLA antibodies, or male donors. All donors were screened for transfusion-transmitted infections (HIV, HBV, HCV, malaria and syphilis) and total SARS-COV-2 antibody titer. None of the donors had previously donated convalescent plasma and they did not donate again for the study. The blood bank is licensed by the regional blood transfusion authority, and the procedure was approved by Institutional Review Board (IRB-1685/DUHS/Approval/2020/).

Convalescent plasma (600–800 ml) was collected by plasmapheresis using a therapeutic apheresis machine (COBE Spectra, Terumo Medical, CO, USA). Collected plasma was aseptically transferred into multiple units for storage at -30°C.

Pre-pandemic fresh frozen plasma (collected before November 2019) was also processed to produce control IVIG.

Preparation of PCP
A PCP batch of 4 ± 0.1 or 8 ± 0.1 l was prepared for subsequent processing by thawing (at 30°C) and pooling frozen convalescent plasma bags from 16–20 individual donors into depyrogenated glass containers under a laminar flow hood. The anti-SARS-CoV-2 antibody titer and concentration of IgG, IgA, IgM and albumin in the pooled plasma was measured before processing.

Caprylic acid precipitation
Precipitation of plasma proteins other than immunoglobulin was carried out in a vertical laminar flow unit by using the caprylic acid precipitation method with modification [18]. The pH was adjusted to 6.0 with 3N HCl and then 5% v/v caprylic acid was added slowly to the PCP with constant vigorous stirring. The vigorous stirring was continued for 1 h at 25°C and pH ~5.0, after which precipitated proteins were removed by centrifugation at 11,000 × g for 30 min at 4°C. The supernatant was filtered before proceeding to ultrafiltration/diafiltration for further purification.

Ultrafiltration/diafiltration
After precipitation, ultrafiltration/diafiltration of the supernatant was performed using a 100-kDa ultrafiltration cassette (Biomax, Merck, NJ, USA) to concentrate immunoglobulin and remove impurities like caprylic acid. The supernatant was aseptically transferred into the feed reservoir of the ultrafiltration equipment (AKTA Flux 6, GE,
Production of hyperimmune anti-SARS-CoV-2 intravenous Ig

Research Article

Uppsala, Sweden) in a laminar flow unit and ultrafiltration/diafiltration was performed at 15 psi pressure drop (ΔP) and transmembrane pressure was manually adjusted at 15 psi. Diafiltration with pyrogen-free formulation buffer (50 mg/ml dextrose and 77 mM NaCl) was performed using six diavolumes and the volume of the retentate was reduced to achieve 5× concentration. The concentrated retentate was collected into a depyrogenated glass container after terminal filtration with 0.2 μm sterile filters (Sartobran, Sartorius, Goettingen, Germany).

Protein quantification & purity profile

Total protein was quantified by automated laboratory system Atellica® chemistry analyzer (Siemens, NY, USA) using the biuret method. The purity profile of the finished product was determined by SDS-PAGE. According to Laemmli (16), stacking (4%) and resolving (10%) gels were prepared (19). The samples were run under reducing and nonreducing conditions, and protein bands were visualized after staining with Coomassie brilliant blue. A reference range marker of 10 to 250 kDa (PageRuler™ Plus Prestained Protein Ladder 10 to 250 kDa, Thermo Scientific, MA, USA) was used.

IgG, IgM, IgA & albumin measurement

The total IgG, IgM, IgA in pooled plasma, control IVIG and C-IVIG were measured by immunoturbidimetry using the Atellica® chemistry analyzer. Albumin was measured by the bromocresol purple dye-binding method using ARCHITECT Systems® (Abbott, IL, USA). Samples that exceeded the detection limit were diluted accordingly.

SARS-CoV-2 antibody titer measurement

Electrochemiluminescence immunoassay was performed for determination of anti-SARS-CoV-2 antibody titer using Elecsys® Anti-SARS-CoV-2 kit (Roche Diagnostics, Basel, Switzerland). The assay is based on the double antigen principle, whereby biotinylated SARS-CoV-2-specific recombinant nucleocapsid antigen and ruthenium-labelled SARS-CoV-2-specific recombinant antigen form a sandwich complex with SARS-CoV-2-specific antibodies. Blood of plasma donor was collected in an acid citrate dextrose vial and centrifuged to collect plasma. The tube containing 1–2 ml plasma was placed in automated electrochemiluminescence analyzer (Cobas e601) for reagent mixing, reaction processing and signal recording. For C-IVIG anti-SARS-CoV-2, antibodies were measured using a 1:4 dilution to avoid any assay limitation. Results were reported as cut-off index (COI), which is based on the ratio of assay signal to cut-off signal (cut-off = 1).

Bioburden analysis

The final product was tested for any potential bioburden. Product sterility was determined in accordance with US pharmacopeia. Tryptic soy broth and fluid thioglycollate medium (Merck, MA, USA) were used and 10% of the sample was inoculated in each of the growth medium (USP-71) (20).

Rabbit pyrogen testing

Healthy rabbits weighing 0.8–1 kg were used. An infusion of 0.03 g/ml was prepared and a dose of 0.15–0.2 g/kg was administered into a marginal vein of the ear of each rabbit. Animals were observed for 3 h and temperatures were recorded at intervals of 30 min (USP-151) (21).

In vivo toxicity assessment

Male Wistar rats of 220–260 g were used after a period of acclimatization. The animals used in this study were maintained in accordance with the ethical guidelines of Dow University of Health Sciences, Karachi, Pakistan.

Animals were divided into three groups of three rats each. IVIG was administered intravenously and dosage was adjusted according to body weight. The first and second groups were considered as low and high dose, respectively (low dosage: 0.3 g/kg; high dosage: 0.5 g/kg) and the control group was administered with saline. All groups were observed daily for behavioral and physical changes for 7 days and then were sacrificed. Blood, liver and kidney samples were collected for hematological and histopathological analysis. Figure 1 shows the process flow diagram for the production of high-titer C-IVIG.

Results

Immunoglobulin concentration

The concentrations of IgG, IgM and IgA were measured in C-IVIG, control IVIG and PCP to compare immunoglobulin composition. The mean concentrations of IgG, IgM and IgA in C-IVIG were found to be 33 ± 4.8,
Convalescent plasma donation

Distribution in multiple units of 200–250 ml

Storage at -30˚C

Thawing at 30˚C

Pooled plasma (16–20 donors)

Batch volume 4 l or 8 l

Addition of 5% caprylic acid, pH 5.0 at 25˚C

stirred for 1 h

Centrifugation at 11,000 xg

Dispensing in final container

Sediments

Supernatant containing immunoglobulins

Ultra-filtration/diafiltration with formulation buffer containing 77 mmol/l NaCl and 50 mg/ml dextrose

Permeate

Retentate

COVID19-IVIG

Figure 1. Process flow diagram for the production of high-titer anti-SARS-CoV-2 intravenously administrable immunoglobulin.

IVIG: Intravenously administrable immunoglobulin.

Anti-SARS-CoV-2 antibody level

The mean level of anti-SARS-CoV-2 antibodies in C-IVIG of eight batches was found to be 104.3 ± 30.3; this was threefold higher than the mean anti-SARS-CoV-2 antibody level in the PCP used for production of batches. The control IVIG produced from prepandemic plasma was found to be nonreactive to SARS-CoV2 antibody. The mean process yield for SARS-CoV2 antibody was found to be 59 % (Figure 2C).
Figure 2. Immunoglobulin content and anti-SARS-CoV-2 antibody level. (A) Comparison of mean IgG, IgM, IgA and anti-SARS-CoV-2 antibody levels in pooled convalescent plasma with that in C-IVIG and control IVIG produced by the caprylic acid precipitation method. Control IVIG (pre-pandemic) was found to be nonreactive for SARS-CoV-2 antibodies. The anti-SARS-CoV-2 antibody level is measured as cut-off index (sample absorbance/cut-off; cut-off = 1). (B) Comparison of IgG, IgM and IgA content (as percentage of total immunoglobulin) in pooled plasma, C-IVIG and control IVIG. (C) Mean percentage yield of IgG, IgA, IgM and anti-SARS-CoV-2 antibodies from convalescent plasma fractionation. All values are represented as the mean of eight consecutive batches of C-IVIG production. C-IVIG: Anti-COVID-19 intravenously administrable immunoglobulin; IVIG: Intravenously administrable immunoglobulin.

Product safety assessment
Each batch of final IVIG product was found to be sterile with no sign of turbidity observed in any liquid culture tube after 14 days of incubation at respective temperatures. SDS-PAGE analysis with 10% separating gel under nonreducing conditions showed a predominant band around 150–160 kDa, confirming the presence of IgG with monomeric IgA. Similarly, under nonreducing conditions two bands of around 50 and 25 kDa were observed, representing the heavy and light chains of IgG (Figure 3). Rabbit pyrogen tests for all batches were cleared. No fever or significant rise in temperature was observed in any of the rabbits, and there were no anaphylactic reactions. Rabbits were observed for a further 1 week, and no mortality was observed.

Toxicity test
Toxicity testing did not show any mortality or behavioral changes in any of the rat groups. No significant difference was observed in their body weights (Supplementary Table 2). Food and water consumption was not remarkably different over the 7-day observation period post-infusion, after which rats were sacrificed.
### Table 1. Characteristics of the anti-COVID-19 intravenously administrable immunoglobulin 5% solution.

| Parameters          | Batch 1       | Batch 2       | Batch 3       | Batch 4       | Batch 5       | Batch 6       | Batch 7       | Batch 8       | Mean ± standard deviation |
|---------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------------------|
| Formulation         | Liquid        | Liquid        | Liquid        | Liquid        | Liquid        | Liquid        | Liquid        | Liquid        | –                         |
| Appearance          | Clear, blue opalescent | Clear, blue opalescent | Clear, blue opalescent | Clear, blue opalescent | Clear, blue opalescent | Clear, blue opalescent | Clear, blue opalescent | Clear, blue opalescent | –                         |
| pH                  | 6.75          | 6.62          | 6.57          | 6.49          | 6.78          | 7.04          | 6.62          | 6.7 ± 0.17    | 6.7 ± 0.17                |
| Osmolality (mOsmol/kg) | 481.5        | 427.5        | 447.5        | 427.5        | 413.5        | 411.5        | 408           | 409           | 428.2 ± 25.3              |
| Total proteins (g/l)| 42            | 45            | 50            | 44            | 43            | 43            | 48            | 52            | 45.9 ± 3.7                |
| IgG (%)             | 79.8          | 81.8          | 77.7          | 78.6          | 79.7          | 79            | 80.8          | 83.8          | 80.1 ± 1.9               |
| IgA (%)             | 15.5          | 15.2          | 18.4          | 17.6          | 17.0          | 17.3          | 14.2          | 11.5          | 15.8 ± 2.2               |
| IgM (%)             | 4.7           | 3.0           | 3.9           | 3.8           | 3.3           | 3.6           | 5.0           | 4.7           | 4.0 ± 0.7                |
| Albumin (g/dl)      | <0.4          | <0.4          | <0.4          | <0.4          | <0.4          | <0.4          | <0.4          | <0.4          | <0.4 †                   |
| Anti-SARS-CoV-2 (COI)| 111.1        | 131.3        | 140           | 122.1         | 46.5          | 106.9         | 77.6          | 99.6          | 104.4 ± 30.4             |
| Pyrogen test        | passed        | passed        | passed        | passed        | passed        | passed        | passed        | passed        | –                         |
| Sterility           | passed        | passed        | passed        | passed        | passed        | passed        | passed        | passed        | –                         |

† Below detection limit.

COI: Cut-off index.

---

**Histopathological examination**

Histopathological examination (Figure 4) of liver from animals treated with two different doses (0.3 and 0.5 g/kg) of IVIG showed no distortion of cells; that is, the findings were similar to those in the control group. Moreover, there were no signs of injury, fatty acid accumulation or hemorrhagic regions around the central vein or sinusoids of the liver. Arrangement of hepatocytes around the cords was visible. Cross-sections of liver revealed that there was no infiltration of lymphocytes, neutrophils, or macrophages and that none of the blood cells were lysed. In the kidneys, mild vascular congestion was observed in both test and control groups. However, no evidence of necrosis, inflammation, atypia or any significant pathological change was seen.

**Hematological assays**

Hematological assays showed no significant changes in most of the parameters, apart from an eosinophil count higher than the standard range; however, increased levels of Mean corpuscular volume (MCV) and lymphocytes were observed in all the studied groups, including control group (Supplementary Table 3).

**Biochemical parameters**

Liver function tests of all the tested groups showed slight increases in direct bilirubin and alkaline phosphatase levels when compared with the standard range; these increased levels were also observed in the control group that was only infused with normal saline (Supplementary Table 4).

**Discussion**

Although limited data are available regarding mechanisms of immune protection against SARS-CoV-2, it is believed that anti-SARS-CoV-2 neutralizing antibodies play a crucial role. Passive immunization in general, and hyperimmune IVIG in particular, is used against a few infectious diseases [22], especially in the case of life-threatening situations and novel viral outbreaks such as SARS-CoV-2, where there is an absence of licensed medication or a specific treatment modality [12,23]. Currently, convalescent plasma and nonspecific IVIG are under trial [24], and a safe and effective treatment through hyperimmune IVIG is of great interest [25].

In this study, C-IVIG was prepared using convalescent plasma mostly obtained from recovered individuals who had mild or moderate symptoms, while severely ill patients were avoided due to donor health concerns. As reported by Weidner et al. [26], donors were found to be reactive for antibodies with highly variable antibody titers due to being at different stages of recovery. Pooling convalescent plasma from 16–20 donors not only provides consistent raw material despite variability in individual plasma, but would also be expected to enhance polyvalency of neutralizing
Figure 3. SDS-PAGE. Patterns of eight consecutive batches of IVIG in (A) non-reducing and (B) reducing conditions. B1–B8: Batch numbers; IVIG: Intravenously administrable immunoglobulin; Mw.M: Molecular weight markers (10–250 KDa).

antibodies, which is expected to increase effectiveness of the C-IVIG. However, the polyvalency of C-IVIG in particular has not been proven in this study. The selection of local plasma donors may also provide antibodies against a variety of indigenous SARS-CoV-2 strains, instead of using monoclonal antibodies that provide protection against one specific strain of virus.

Unlike commercially predominant methods for IVIG production, such as cold ethanol fractionation [27], the C-IVIG product development strategy detailed in this study involved limited processing steps and simpler techniques. This ensures practicality and feasibility of the manufacturing process to address the urgent global need for widespread availability during the COVID-19 pandemic. A combination of caprylic acid precipitation and tangential flow filtration led to the preparation of high-titer C-IVIG. Consistency and robustness of the product in eight consecutive batches was indicated after analysis of IgG, IgM and IgA concentrations. Owing to process losses at different stages
of production, an overall process yield of 68% was achieved, comparable to that of similar processes reported by Morais et al. and El-Ekiaby et al. [17,18]. The percentage composition of immunoglobulin in C-IVIG and PCP (80% IgG, 15% IgA and 5% IgM) was found to be similar to that in serum of normal healthy individuals [28–30], suggesting efficiency of the production process and physiological suitability of the product. One of the limitations in this work was the failure to minimize IgA concentration in C-IVIG [31] for compatibility with IgA deficient patients, through inclusion of further purification steps. However, given that IgA can serve as a SARS-CoV-2-neutralizing antibody [32], the inclusion of further steps would decrease the yield of the process where availability of convalescent plasma was already a limitation.

The use of 5% caprylic acid for precipitation in this method also ensures the inactivation of enveloped viruses, as it is known to disrupt the lipid envelope and inactivate enveloped viruses completely in immunoglobulin solutions [17]. Ultrafiltration/diafiltration is used to remove residual caprylic acid from solution after caprylic acid precipitation, followed by the addition of formulation buffer containing stabilizers and purification and concentration of the solution to the desired 5% preparation [33–35].

Due to unavailability of SARS-CoV-2 neutralization assays, the SARS-CoV-2 antibody titer was determined using the Elecsys® kit. The kit is reported to have sensitivity of 95% and it showed significant correlation with neutralization test (NT) titers [26]; hence it was used as an alternative to NT for donor screening and titer measurement in PCP and C-IVIG. However, using Elecsys is a limitation in our study and is not recommended when NT or other strongly correlated tests are available. The mean titer of 104 COI is considered high compared with the titer in convalescent plasma collected for this study, which had a mean of 36 COI and reached a maximum of 60 COI for an individual donor. Control IVIG prepared from pre-pandemic plasma was found to be nonreactive for SARS-CoV-2 antibodies, consistent with data reported by Yang et al. [36], so it can be deduced that commercially available nonspecific IVIG made in the prepandemic era will not be able to neutralize SARS-CoV-2.
The formulation buffer used in C-IVIG preparation contains dextrose and sodium chloride (50 g/l dextrose and 77mM NaCl). The dextrose serves as a stabilizing agent for immunoglobulin at pH >4.5, as in the case of C-IVIG where pH was maintained around physiological pH (∼7). The sodium concentration in the buffer was comparable to that of commercial IVIG preparations, to form a hypotonic solution (0.45% saline) [31]. Hence the osmolality of C-IVIG was also within the range of commercially available IVIG products [37]. Safety of the formulation was further tested on rats to observe any toxic, pathological or adverse effects in vivo. Rabbit pyrogen test was used instead of the Limulus amebocyte lysate assay to check for pyrogenicity of C-IVIG, due to interfering factors in blood-derived products that limit bacterial endotoxin measurement through the Limulus amebocyte lysate assay [38]. Although the reuse of animals for rabbit pyrogen tests is common, it is not recommended for immunogenic preparations; hence rabbits used once were not used again. Product stability tests are being conducted, however sufficient data are not currently available.

Conclusion
With multiple treatment modalities against COVID-19 still under trial, this study aimed to develop a method based on passive immunization through IVIG produced from COVID-19 convalescent plasma collected locally. The C-IVIG production method applied in this study is feasible, practical and could be implemented at local level using indigenously collected convalescent plasma against local SARS-CoV-2 strains. The process resulted in a product that was safe, effective and physically comparable to commercially available IVIG. The 5% C-IVIG solution comprised 90% immunoglobulin (IgG, IgM and IgA) with a total anti-SARS-CoV-2 antibody titer three-times higher than in PCP, which makes this treatment potentially more effective than the other passive immunization methods available. The C-IVIG will be used in a registered clinical trial (NCT 04521309) for further evaluation of its safety and efficacy.

Summary points
- SARS-CoV-2 infection has emerged as a global health crisis with no particular licensed treatment available at the time of writing.
- The effectiveness of passive immunization using convalescent plasma and nonspecific intravenously administrable immunoglobulin is yet to be established for COVID-19.
- Experts believe hyperimmune intravenous immunoglobulin preparation can be a safe and effective therapeutic option against COVID-19 until an approved vaccine or medication becomes available.
- In this study convalescent plasma from COVID-19 recovered individuals was collected through plasmapheresis, then pooled and fractionated by a modified caprylic acid precipitation method to produce anti-COVID-19 intravenous immunoglobulin (C-IVIG).
- The C-IVIG preparation is a liquid formulation that can be administered intravenously into COVID-19 infected individuals in early stages to neutralize SARS-CoV-2.
- C-IVIG is prepared by caprylic acid precipitation of pooled COVID-19 convalescent plasma, followed by ultrafiltration/diafiltration to concentrate immunoglobulins.
- Analytical assessment of C-IVIG confirmed its safety.
- The product has been registered for clinical trials to evaluate its safety and efficacy in patients with SARS-CoV-2 infection.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2020-0263

Author contributions
S Ali was responsible for concept design, supervision, laboratory experimentation, critical analysis and drafting and finalization of the manuscript. S Uddin was responsible for process design optimization, laboratory experimentation, critical analysis and drafting and finalization of the manuscript. A Ali performed process quality control, laboratory experimentation, critical analysis and drafting and finalization of the manuscript. M Khan performed process quality control, laboratory experimentation, critical analysis and drafting of the manuscript. F Anjum and R Ali performed process design optimization, laboratory experimentation and critical analysis. E Shalim carried out laboratory experimentation, data acquisition and critical analysis. I Ahmed and U Bukhari performed laboratory experimentation and drafting of the manuscript. S Muhaymin performed laboratory experimentation and critical analysis. S Luxmi was responsible for the collection of raw material and addressed clinical needs. A Khan provided expert
advice and was responsible for process design approval and finalization of the manuscript. S Quraishy was responsible for concept design, process design approval and finalization of the manuscript.

Financial & competing interests disclosure
The authors received funding from Dow University of Health Sciences and Higher Education Commission Pakistan grant number: 20-RRG-134/RGM/R&D/HEC/2020. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval for animal experimental investigations. Ref IRB-1685/DUHS/Approval/2020/79. The animals used in this study were maintained in accordance to the ethical guidelines of Dow University of Health Sciences, Karachi, Pakistan.

References
Papers of special note have been highlighted as: • of interest
1. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11), 1061–1069 (2020).
2. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497–506 (2020).
3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 109, 102433 (2020).
4. World Health Organization. Coronavirus disease (COVID-19) pandemic (2020). www.who.int/emergencies/diseases/novel-coronavirus-2019
5. Fernandes N. Economic effects of coronavirus outbreak (COVID-19) on the world economy. IESE Business School Working Paper No. WP-1240-E. doi:10.2139/ssrn.3557504 (2020) (Epub ahead of print)
6. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Critical Care 24(1), 91 (2020).
7. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 1–7 (2021).
8. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20(4), 398–400 (2020).
   • Supported the concept of our study.
9. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 368, m1256 (2020).
   • Supported the concept of our study.
10. Shen C, Wang Z, Zhao F et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323(16), 1582–1589 (2020).
   • Supported the concept of our study.
11. Chai KL, Valk SJ, Piechotta V et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst.Rev. 10, CD013600 2020).
12. Cao W, Liu X, Bai T et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect. Dis. 7(3), ofaa102 (2020).
13. Xie Y, Cao S, Li Q et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J. Infect. 81(2), 318–356 2020).
14. Salazar G, Zhang N, Fu TM et al. Antibody therapies for the prevention and treatment of viral infections. NPFV Vaccines 2, 19 (2017).
15. De Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EbioMedicine 55, 102768 2020).
   • Clarified IVIG’s potential mode of action in COVID-19.
16. León G et al. Industrial Production and Quality Control of Snake Antivenoms. In: Toxicology. Gopalakrishnakone P, Calvete J. (Eds). Springer, Dordrecht (2014).
17. El-Ekiaby M, Vargas M, Sayed M, et al. Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. PLoS Negl. Trop. Dis. 9(2), (2015).
   • Provided evidence on human plasma fractionation through caprylic acid precipitation.
18. Morais V, Berasain P, Massaldi H. Immunoglobulin purification by caprylic acid. Protein Downstream Processing. Humana Press, NJ, USA 137–143 (2014).
• Provided a standard to compare the process efficiency.

19. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227(5259), 680–685 (1970). U.S. Pharmacopeia. USP-71, Sterility tests. United States Pharmacopeia and National Formulary, USP 41-NF 36 U.S. Pharmacopeial Convention, MD, USA, 5984–5991 (2018).

21. U.S. Pharmacopeia 41. 151 Pyrogen Test. United States Pharmacopeial Convention, Inc. MD, USA,6083–6085 (2018).

22. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13(4), 602–614 (2000).

23. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA 117(17), 9490–9496 (2020).

24. Abrams-Downey A, Szabiye J, Vidaurrezaga M. Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials. Eur. Urol. Focus 6(5), 1028–1031 (2020).

25. Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, Mcdonald DR. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! Clin. Immunol. 216, 108459 (2020).

• Provided evidence on the possible role of hyperimmune immunoglobulin therapy for COVID-19.

26. Weidner L, Gänssdorfer S, Unterweger S et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J. Clin. Virol. 129, 104540,2020).

• Provided authentication of the Elecsys system used to quantify anti-SARS-CoV-2 antibodies.

27. Barahona Afonso AF, João CMP. The production processes and biological effects of intravenous immunoglobulin. Biomolecules 6(1), 15 (2016).

28. Harlow ED, Lane D. Antibodies: a Laboratory Manual. Cold Spring Harbor Laboratory, NY, USA, 579 (1988).

29. Alberts B, Johnson A, Lewis J, Morgan D, Raff M, Keith Roberts PW. W. W. Norton & Company Molecular Biology of the Cell NY, USA . (2018).

30. Fundenberg HH, Stites DP, Caldwell JL, Wells JV. Basic and Clinical Immunology. Lange Medical Publications, CA, USA (1976).

31. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox. Sang. 98(1), 12–28 (2010).

32. Wang Z, Lorenzi JC, Muecksch F et al. Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro. bioRxiv doi:10.1101/2020.09.09.288555 2020) (Epub ahead of print).

33. Parkkinen J, Rahola A, Von Bonsdorff L, Törmä T, Törmä E. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox. Sang. 90(2), 97–104 (2006).

34. Kothe N, Rudnick D, Piechaczek D, Klein H, Rohm D, Kloft M (Manufacturing intravenous tolerable immunoglobulin-g preparation US5164487A United States 1992).

35. Vargas M, Segura A, Wu YW et al. Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity. Vox. Sang. 108(2), 169–177 (2015).

36. Yang R, Lan J, Huang B et al. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine 58, 102890 2020).

37. Abolhassani H, Asgardoone MH, Rezaei N, Hammarstrom L, Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?. Expert. Rev. Clin. Immunol. 11(11), 1229–1243 (2015).

38. Ochiai M, Yamamoto A, Naito S et al. Applicability of bacterial endotoxins test to various blood products by the use of endotoxin-specific lysates. Biologicals 38(6), 629–636 (2010).